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individuals with high serum HIV loads, responsive to optimal
anti-retroviral treatment. Published cases of ALS-like disease in
HIV are mostly newly diagnosed and untreated cases of HIV.
Bowen et al recently described 5 cases of HIV-MND in men,
mostly young, where the ALS manifestations improved with
ARV treatment and detected activity of an endogenous retrovi-
rus, HERV-K in 4 of 5 cases (Human Endogenous Retro-
Virus-K). Here, we describe three cases of MND in HIV posi-
tive individuals that differ from previously published cases in
having well-controlled HIV on anti-retroviral treatment (ARV)
with 0 viral titres in CSF and serum. Interestingly, in one
case, a research assay for HERV-K was negative, although this
tool is not yet clinically validated. Further research will be
required to determine the aetiological relevance of endogenous
retroviruses in MND in individuals who are HIV positive or
otherwise immunologically-compromised. Likewise, whether
endogenous retrovirus activity occurs in sporadic ALS/MND
remains to be determined.
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Purpose Recommendations by International League Against
Epilepsy (ILAE) Non-epileptic Seizures Task Force propose a
four-level hierarchical approach (using history, witnessed event,
electroencephalographic (EEG)) to establish Non-Epileptic
Attack Disorder (NEAD) diagnosis. We describe clinical charac-
teristics, diagnostic certainty level, investigation pathways and
management strategies of patients at a specialist neuropsychia-
try clinic.
Method Medical notes of 148 patients with NEAD attending
between September 2012 – 2015 were reviewed.
Results Patient categorisation (Females: n=108, 73.0%; Disease
duration: 7.9 years (SD 10.4)) was mainly based on clinical
features and EEG findings; only 7 (4.7%) patients had attacks
witnessed by a specialist. Largest diagnostic categories were
‘possible’ (less robust) (n=54; 36.5%), ‘clinically-established’
(moderately robust) (n=40; 27.0%), then ‘documented’ (most
robust) (n=12; 8.1%), ‘probable’ (n=5; 3.4%) (moderately
robust). EEG was most commonly performed (n=125;
84.4%), then neuro-imaging (MRI: n=100, 67.6%). 48
(32.4%) had further neurological/cardiac/vestibular/sleep test-
ing. There were no differences in pharmacological/behavioural
management across categories.
Conclusion Difficulty in witnessing clinical events in person/on
video recording/EEG limits clinical application of diagnostic
recommendations, and thereby more robust diagnostic catego-
risation. Displaying video-footage in clinic could improve diag-
nostic certainty. Adherence to recommendations may help
streamline investigation paths, reducing diagnostic delays. Irre-
spective of categorisation, pharmacological and behavioural
interventions are implemented.
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Neurological disease is responsible for a huge burden of death
and disability in sub-Saharan Africa. However, average number
of Neurologists in these countries can be as low as 0.3/mil-
lion. Consequently, most doctors will qualify from medical
school without having been taught by a Neurologist. NeuroAc-
cess aims to provide a sustainable programme of targeted clin-
ical neurology education in Zambia and Mozambique. The
NeuroAccess team is a small group of Registrars, Clinical Lec-
turers, and Consultants, who provide a bi-annual intensive
clinical teaching programme to doctors and students, in coor-
dination with the local curriculum. With the support of the
ABN, the Encephalitis society and the UK-based NeuroPACES
course, NeuroAccess is delivered annually since 2013 provid-
ing teaching to an estimate of 60 medical students and 20
doctors on each visit. The whole programme is made possible
thanks to colleagues working on the ground throughout the
year. In collaboration with these locally based, physicians the
aim is to incorporate NeuroAccess in a long-term programme
of formal post-graduate neurological specialist training. Our
aim is to improve the depth and breadth of practical skills in
clinical neurology to empower a cadre of local doctors to
manage the many neurological problems in these countries.
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Involving patients and carers in service improvement projects
is an essential aspect of patient-centred care, but happens only
rarely. It can bring new perspectives and improve knowledge,
health care engagement and health outcomes. While guidelines
are available supporting public involvement in service improve-
ment, these do not address the specific needs of patients with
PD. The aim of this project is to develop an easy-to-use guide
for service development project leads and patients/carers. This
will facilitate the involvement of the latter in the development
and implementation of PD service improvements. We used a
semi-structured interview to capture good practice and barriers
to service user involvement at each stage of service develop-
ment. Local clinicians, patients and carers who have been
involved in service improvement projects were invited to par-
ticipate in telephone interviews. Key themes from initial
grounded analysis of the data include: Access, including
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physical access to rooms and offering alternatives such as tele-
conferences or video calls; Representation, ensuring a wide
range of patients are able to be involved; and Empowerment,
enabling patient voice to be heard. The themes will describe
how patients have been involved projects and how this could
be done better; they will then inform further discussion by a
focus group to define and develop the guide.
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Compared with cutting needles, use of atraumatic pencil-point
needles significantly reduces incidence of post-lumbar puncture
headache. Many physicians still use cutting needles for lumbar
puncture (LP), despite the comparatively higher morbidity and
consequent monetary cost.
Clinical Case A patient underwent diagnostic lumbar punctures
with a cutting needle. The resulting CSF leak identified on
MRI required treatment with a blood patch. Following this
procedure, he developed a severe systemic inflammatory
response. These complications prolonged his admission by 4
weeks.
Audit We audited ward and daycare stock of spinal needles in
our Trust, and surveyed local junior doctors regarding their
knowledge and experience of different needles for lumbar
puncture.
Results 87% of stocked needles were cutting needles. 76% of
trainees surveyed knew no differences between atraumatic and
cutting needles and only 8% had used atraumatic needles
before.
Action A series of LP workshops were delivered to trainees.
Benefits of atraumatic needles were explained and LP techni-
que using atraumatic needles was taught on a manikin.
Conclusions Due to the rotational nature of doctors’ training,
the atraumatic needles LP workshop will need to be delivered
again at regular intervals in the future. Other Trusts would
benefit from developing similar training sessions.
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Autoantibodies against glycine receptors (GlyRAbs) are found
in half of patients with progressive encephalomyelitis with
rigidity and myoclonus (PERM), and in patients with related
acquired neurological syndromes (Carvajal-Gonzalez, 2014).
The clinical features of PERM are consistent with disruption
of spinal and brainstem inhibitory circuits. However, the pre-
sumed role of GlyRAbs in neurological disease is based largely
on circumstantial clinical evidence. Using whole-cell patch-
clamp we recorded spontaneous miniature glutamatergic and
glycinergic postsynaptic currents from motoneurons in rat spi-
nal cord cultures. We compared the currents in neurons incu-
bated in IgG purified from patients with GlyRAbs or controls.
IgG from patients selectively and severely disrupts glycinergic
neurotransmission. Such disruption of inhibition in vivo would
be consistent with many of the clinical features of PERM.
Our electrophysiological findings therefore provide strong evi-
dence that the antibodies in these cases are pathogenic. GlyR-
Abs internalise glycine receptors in HEK293 cells, but we find
that they induce failure of glycinergic neurotransmission in
neurons within 30 min at room temperature suggesting that
they also directly antagonise glycine receptors. Alongside these
investigations we are using clinical neurophysiology to identify
affected circuits in GlyRAb patients. Findings are compared to
patients with genetic defects in glycinergic pathways (heredi-
tary hyperekplexia) and healthy controls.
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The Gatsby/Wellcome Neuroscience Project is a Royal College
of Psychiatrists (RCPsych) two-year initiative to bridge the gap
between psychiatry and neuroscience and introduce a modern
neuroscience perspective into psychiatrists’ clinical work. The
Core Curriculum for psychiatric trainees is being reshaped to
incorporate advances from basic and clinical neuroscience
research that are dramatically changing our understanding of
how the brain works. This will: 1. Equip trainees for the sci-
entific advances that will be made over their working lives by
ensuring that they are ‘neuroscientifically literate’ 2. Better
prepare psychiatrists to develop and deliver innovative bio-
medical approaches to patient care as they become available
The first phase of the Project featured extensive consultation
among members of the RCPsych, and a recurring theme was
a desire among psychiatrists for increased training in neurol-
ogy. We found a positive environment for collaboration and
significant interest in exploring joint initiatives with organisa-
tions such as the ABN. A survey of neurologists in the ABN’s
Cognitive Special Interest Group and of the Chairs of Advi-
sory Groups revealed strong enthusiasm for the inclusion of
psychiatry as a routine part of the training of neurology regis-
trars. The Gatsby/Wellcome Neuroscience Project represents
the ideal opportunity to develop such initiatives.
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Spinal Dural Arteriovenous Fistula (SDAVF) is the most com-
mon vascular abnormality of the spinal cord; however in clini-
cal practice it is rare with average time to diagnosis of 22
months. SDAVF is a cause of reversible myelopathy, hence the
importance of diagnosis and early treatment. Here we present
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